This page will be updated frequently:
What is PT2977:
An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor PT2977 binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.
Drug Manufacturer: https://www.pelotontherapeutics.com
Articles:
Oct 7, 2019
Oct 1, 2019
Apr 9, 2019https://www.businesswire.com/news/home/20190409005275/en/Peloton-Therapeutics-Announces-Completion-Enrollment-Phase-2
Sep 29, 2019
Apr 1, 2019Last updated: 01/08/2020
Check for active clinical trials
Comments
Post a Comment